KELYNIAM GLOBAL INC - KLYG STOCK NEWS

Kelyniam Global (KLYG) reported strong Q3 2024 financial results, with total revenue reaching $2,492,607, a 43% increase from the previous year. The company's gross margin grew 44% to $1,956,714, while operating profit improved significantly to $273,248 from a loss of ($329,993). EBITDA also turned positive at $349,099 compared to previous year's loss.

The company attributes its success to overnight service, quality focus, new surgeon acquisitions, and effective expense management. Notable developments include increased market acceptance of CustomizedBone™ regenerative implant and NEOS Cranial Loop fixation products.

Kelyniam Global (OTC: KLYG), a custom cranial implant manufacturer, reported strong financial results for the first half of 2024. The company saw significant improvements across key metrics:

- Total revenue increased by 49.01% to $1,709,239
- Gross margin grew 52.7% to $1,330,965
- Operating profit reached $172,093, up from a loss of $229,345
- EBITDA improved to $197,355 from a loss of $204,691

The company attributes this growth to increased sales, efficiency improvements, and reduced expenses. Kelyniam's patented integrated fixation in PEEK implants and CustomizedBone™ hydroxyapatite implants gained market acceptance. The company also held its annual shareholder meeting, participated in industry events, and announced FDA clearance for a partner product.

Kelyniam Global (OTC: KLYG) reported a significant improvement in its Q1 financials for the quarter ending March 31, 2024. Revenue increased by 60.5% to $957,447, while the gross margin rose by 59.0% to $743,719. The company achieved an operating profit of $123,599, a notable turnaround from a loss of $67,978 in the same period last year, largely due to decreased consulting and IT costs. Surgeons and distributors increasingly use Kelyniam's custom cranial and craniofacial implants, contributing to sales momentum from Q4 into Q1. Interest in the CustomizedBone hydroxyapatite osteo-integrative cranial implant is growing, especially for pediatric patients, boosted by the approval of the NEOS Cranial Loop fixation method. The annual Shareholder Meeting will be held on June 24 at 8:30 am Central. Full financial details are available on the company's website.

Kelyniam Global and Fin-ceramica's NEOS Surgery Cranial LOOP™ fixation system receives 510(k) clearance from the FDA for use with CustomizedBone™ hydroxyapatite cranial implants. The system, made of PEEK-OPTIMA™, offers rapid fixation, low infection rate, and pediatric indication, enhancing Kelyniam's sales momentum.

Kelyniam Global (KLYG) reported a 12% decrease in total revenue for the year ended December 31, 2023, despite setting a quarterly unit sales record in Q4. The company attributed the revenue decline to strategic investments in personnel and infrastructure earlier in the year. The CEO highlighted a 40% unit and revenue growth in Q4, driven by new sales representatives and a competitor's exit from the market. Kelyniam aims to capitalize on this opportunity by offering innovative implant solutions.

Kelyniam Global (OTC:KLYG) reports third-quarter results with a temporary sales slowdown but remains optimistic.

Kelyniam Global (OTC:KLYG) announced its half-year financial results, reporting flat unit sales for the first half of 2023 compared to the previous year. The company attributes this to timing issues affecting revenue recognition. Despite this, the CEO remains optimistic about sales and revenue growth in the latter half of the year. Financial highlights include a 21.9% decrease in total revenue, a decrease in gross margin, and an operating loss compared to operating income in the prior year.

Kelyniam Global (OTC: KLYG), a manufacturer of custom cranial implants, reported a 13.2% increase in total revenue for 2022, reaching $3,017,599 compared to $2,664,434 in 2021. However, the company recorded a net loss of $97,560 after posting a net income of $201,741 in the previous year. The decline in profitability was attributed to non-cash legacy stock awards and operating income fell to $69,322 from $180,445. CEO Ross Bjella highlighted the company's competitive edge in manufacturing and rapid delivery of custom implants and outlined plans for future product development and licensing in the neurosurgery market.